98%
921
2 minutes
20
Background: The use of electrophoresis to monitor monoclonal immunoglobulins migrating in the β fraction may be difficult because of their comigration with transferrin and complement proteins.
Methods: Immunoassays specific for IgGκ, IgGλ, IgAκ, IgAλ, IgMκ, and IgMλ heavy/light chain (HLC) were validated for use in the clinical laboratory. We assessed sample stability, inter- and intraassay variability, linearity, accuracy, and reference intervals for all 6 assays. We tested accuracy by verifying that the sum of the concentrations for the HLC-pairs accounted for the total immunoglobulins in each of 129 healthy sera, and that the HLC-pair ratios (rHLCs) were outside the reference interval in 97% of 518 diagnostic multiple myeloma (MM) samples.
Results: We assessed diagnostic samples and posttreatment sera in 32 IgG and 30 IgA patients for HLC concentrations, rHLC, and total immunoglobulins and compared these nephelometry results with serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE). In sample sets from patients with IgG MM, the sensitivity of SPEP was almost the same as for rHLC, and no additional advantage was conferred by running HLC assays. In pre- and posttreatment samples from patients with IgA MM, the SPEP, rHLC, and IFE identified clonality in 28%, 56%, and 61%, respectively. In addition, when M-spikes were quantifiable, the concentration of the involved HLC was linearly related to that of the SPEP M-spike, with a slope near 1.
Conclusions: The use of IgA HLC assays for monitoring β-migrating IgA monoclonal proteins can substitute for the combination of SPEP, IFE, and total IgA quantification.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1373/clinchem.2014.231985 | DOI Listing |
Neurol Sci
September 2025
Department of Neurosurgery, The 940, Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, No.333 Nanbinhe Road, Qilihe District, Lanzhou City, Gansu Province, China.
Ann Hematol
September 2025
Hematology and Transplant Center, University Hospital"San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
Functional high risk multiple myeloma (FHRMM) remains a challenging entity with poor outcomes and limited survival, and there is no international consensus on optimal second-line therapeutic strategies in relapsed/refractory patients. In this multicenter real-world retrospective study, we investigated clinical characteristics and outcomes of a total of 62 FHRMM patients previously treated with a first-line daratumumab-based quadruplet regimen or who relapsed within 12 months after frontline autologous stem cell transplantation (ASCT). In our cohort, the overall response rate was 61%, with 42% of patients achieving a very good partial response (VGPR) or better.
View Article and Find Full Text PDFClin Lymphoma Myeloma Leuk
August 2025
HBS Medical and Dental College, Islamabad Pakistan.
Blood
September 2025
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
Isatuximab is an IgG1k monoclonal antibody that binds with high affinity to CD38 expressed on plasma cells. Anti-CD38 antibodies have shown efficacy as monotherapy and in combination in a variety of settings for patients with multiple myeloma and light chain (AL) amyloidosis. This multi-center, cooperative group phase 2 trial was designed to evaluate hematologic response, organ response, and safety of isatuximab monotherapy for the treatment of relapsed AL amyloidosis.
View Article and Find Full Text PDFEur J Cancer
August 2025
Emory University, Atlanta, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA; Atlanta Veterans Administration Medical Center, Atlanta, USA. Electronic address:
Background: Early detection of hematological malignancies improves long-term survival but remains a critical challenge due to heterogeneity in clinical presentation. Chronic inflammation is a key driver in hematologic cancers and is known to induce compensatory microvascular changes. High-resolution, non-invasive retinal imaging can allow the quantification of microvascular changes for the early detection of hematological malignancies.
View Article and Find Full Text PDF